09:51 AM EDT, 07/22/2024 (MT Newswires) -- aTyr Pharma, Inc. ( ATYR ) said Monday it has completed enrollment in its phase 3 trial of efzofitimod to potentially treat people with pulmonary sarcoidosis.

The trial enrolled 268 people at 85 centers in nine countries and exceeded its target enrollment, the company said, adding that topline results are expected in Q3 2025.

Pulmonary sarcoidosis is a type of interstitial lung disease that has limited treatment options, aTyr said.

aTyr shares were rising past 2% in recent trading.

Price: 1.67, Change: +0.03, Percent Change: +1.83